We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Analytical Cannabis Logo
Home > News > Policy > Content Piece

UK Medical Cannabis Firm Announces New Import Deal

By Alexander Beadle

Published: Jun 22, 2020   
Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.

LYPHE Group, formerly the medical division of European Cannabis Holdings, is a British medical cannabis firm that operates as a leading distributor and clinical services provider within the cannabis space.

On Monday, June 15, LYPHE Group announced a new partnership with Eaststone Ltd to secure import, distribution, and other ancillary services relating to the cannabis sector in the United Kingdom.

LYPHE Group announces agreement with Eaststone Ltd

Eaststone is one of the national market leaders in the supply of unlicensed medicines in the UK, serving over 700 physical pharmacy locations across the country.

In a press statement, LYPHE Groups CEO Dean Friday, commented, We are very proud to be working with the Day Lewis, Cohens and Eaststone Group. This agreement, especially the distribution capabilities that it presents, is a major breakthrough for our business and of significant strategic importance with respect to the distribution and value-adding activities that we look to provide under the agreement. The UK market is at break-out phase meaning that more and more patients are receiving the life-changing medicine to help them treat chronic and debilitating medical conditions.”

LYPHE Group is currently responsible for over 50 percent of all new prescriptions being written for medical cannabis in the UK, and has amassed a number of different distribution agreements with medical-grade cannabis cultivators around the world.

Improving medical cannabis access in the UK

Since the UK began allowing for medical cannabis treatments in late 2018, many patients have struggled to effectively access the cannabis-based medicinal products (CBMPs) that are supposed to be available to them. Very few patients have been prescribed such CBMPs through the National Health Service (NHS), partly due to a lack of education among medical professionals and restrictions on bulk imports.

To address these problems, institutions like the Academy of Medical Cannabis have been set up to improve medical understanding. The UK Government also announced in March that it would be ending the national restriction on bulk imports of medical cannabis in order to address the long delays that patients faced with accessing their prescribed medicines. Slowly, spurred on by the hard work of organizers and campaigners, the United Kingdom is making meaningful changes towards improving access for patients.

“Our country is shifting its mindset positively towards medical cannabis. It is becoming a well-used, well examined and well thought of natural alternative to the horrid, and sometimes deadly pharmaceuticals that have been pumped into our bodies for far too many years,” LYPHE Group’s managing director Jonathan Nadler told Analytical Cannabis.

“Our job is to build the infrastructure that can allow better access for patients, at more affordable prices and across as large a range of products as possible. That is what this new partnership with Eaststone will enable us to achieve.”


Like what you just read? You can find similar content on the topic tag shown below.


Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter